Skip to content

3 Mid-Year Mid-Cap Biotech Picks

“All three picks can be volatile but very tradable and should be considered as long term holds with expectations for growth, positive clinical data or M&A.”

Biotech Gets Some Love From The FDA – And Redditors

After trailing the broader market for the past few months, biotech has gotten some love in recent days – from the FDA in the form of its approval of Biogen’s controversial Alzheimer’s drug, and also from the Reddit crowd.